^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

KRAS mutation + PIK3CA wild-type

i
Entrez ID:
Related biomarkers:
over1year
KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics. (PubMed, Crit Rev Oncol Hematol)
The backbone of common KRAS and PIK3CA mutations is a rational frame for development of therapeutic algorithms in colorectal cancer and can help guide new drug therapies development. In addition, the prevalence of different molecular groups presented here may help with planning of combination clinical trials by providing estimations of sub-sets with more than one alteration.
Review • Journal • IO biomarker
|
KRAS (KRAS proto-oncogene GTPase) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
|
KRAS mutation • BRAF mutation • PIK3CA mutation • ATM mutation • ARID1A mutation • KRAS wild-type • RAS wild-type • PIK3CA wild-type • PIK3CA mutation + KRAS mutation • KRAS mutation + PIK3CA wild-type • PIK3CA mutation + RAS wild-type